Abbott Reports Second-Quarter 2025 Results

Go back to Abbott Reports Second-Quarter 2025 Results

Abbott Labs (ABT) PT Lowered to $155 at Citi

July 18, 2025 10:03 AM EDT

Citi analyst Joanna Wuensch lowered the price target on Abbott Labs (NYSE: ABT) to $155.00 (from $157.00) while maintaining a Buy rating.

The analyst comments "This was a somewhat precarious setup for ABT heading into the quarter, priced for a beat-and-raise, which did not... More

Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)

July 17, 2025 9:45 AM EDT

Goldman Sachs analyst David Roman reiterated a Buy rating and $153.00 price target on Abbott Labs (NYSE: ABT).

The analyst comments "This morning, Abbott reported 2Q25 results and updated 2025 guidance. The headline that we expect to gain most attention is the reduction to the... More

Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance

July 17, 2025 7:31 AM EDT

Abbott (NYSE: ABT) reported Q2 EPS of $1.26, $0.01 better than the analyst estimate of $1.25. Revenue for the quarter came in at $11.42 billion versus the consensus estimate of $11.07 billion.

GUIDANCE:

Abbott sees FY2025 EPS of $5.10-$5.20, versus the consensus of $5.16.

For earnings history and earnings-related data on Abbott (ABT) click here.

... More